为了改进IPI和R-IPI,特别是确定5年OS小于50%的患者亚组,研究者使用国家癌症综合网络数据库,为接受R-CHOP治疗的新诊断DLBCL患者制定了增强的IPI(NCCN-IPI)评分系统。同样,组成NCCN-IPI的临床危险因素与IPI/R-IPI基本相同,但NCCN-IPI重...
为了克服IPI/R-IPI的劣势,尤其是区分出5年OS率<50%的亚组,利用美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)数据库建立了针对接受R-CHOP治疗的初诊DLBCL患者的增强版评分系统,即NCCN-IPI评分[5]。NCCN-IPI采用的...
In the present study, we demonstrated high CRP levels at diagnosis of DLBCL as an independent poor prognostic factor for clinical outcome. Adding CRP to the well-established prognostic models such as the R-IPI score might improve their predictive ability....
Case Overview: A 64-Year-Old Man with Diffuse Large B-Cell Lymphoma (DLBCL)Case History June 2020: A 64-year-old man presented with DLBCL Stage III disease ECOG PS 2 Serum LDH=3.7 x ULN NCCN-IPI score=6 (High-risk) History of hypertension (well-controlled)...
罗氏成员基因泰克于2023年4月20日宣布,美国食品药品监督管理局(FDA)已批准Polivy与R-CHP联合用于治疗既往未经治疗的弥漫性大B细胞淋巴瘤(DLBCL)、未另作说明或高级别B细胞淋巴瘤(HGBL)以及国际预后指数(IPI)评分为2分或更高的成人患者。注:R-CHP指的是:利妥昔单抗、环磷酰胺、阿霉素和泼尼松。
我的理解：对于初治的中危或高危DLBCL患者，接受pola-R-CHP方案治疗使其疾病进展、复发或死亡的风险均...
医生您好,我爸爸是非霍奇金淋巴瘤(DLBCL-ABC亚型)IV期B组,弥漫大B,IPI评分3分。目前已经做了六次R-CHOP,前两天做的PET结果比较好。主治医生说我爸爸病灶比较广,又是四期,复发的风险高,建议做自体移植。也咨询了另一个医生,说一线方案治疗CR,不推荐做移植。现在家里人很纠结不知道后续该巩固治疗还是做自体移植...
The R-CHOP immunochemotherapy protocol has been the first-line (1L) standard of care (SOC) for diffuse large B-cell lymphoma (DLBCL) patients for decades and is curative in approximately two-thirds of patients. Numerous randomized phase III trials, most
In diffuse large B-cell lymphoma (DLBCL), the age-adjusted International Prognostic Index (aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic treatment. Body mass index (BMI) and gender are occasionally sited as prognostic factors; however, their value ...
出处 《智慧健康》 2022年第29期57-61,65,共6页 Smart Healthcare 关键词 弥漫大B细胞淋巴瘤 RCHOP方案 累及野放疗 IPI评分 血清LDH Diffuse large B-cell lymphoma RCHOP chemotherapy Radiotherapy involving field IPI score Serum LDH 分类号 R733.1 [医药卫生—肿瘤] 登录...